Corneal Melting Two Weeks after Pterygium Excision with Topical Mitomycin C: Successfully Treated with Lamellar Keratoplasty and Amnion Membrane Transplantation by Menghini, Moreno et al.
 
Case Rep Ophthalmol 2012;3:24–29 
DOI: 10.1159/000336452 
Published online: 
January 31, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1663–2699 
www.karger.com/cop 
This is an Open Access article licensed under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable 
to the online version of the article only. Distribution for non-commercial purposes only.   
 
                      Moreno Menghini, MD    Department of Ophthalmology, University Hospital Zurich, Frauenklinikstrasse 24 
CH–8091 Zurich (Switzerland) 
Tel. +41 79 704 52 58, E-Mail moreno @ menghini.biz 
 
24 
   
Corneal Melting Two Weeks after 
Pterygium Excision with Topical 
Mitomycin C: Successfully 
Treated with Lamellar 
Keratoplasty and Amnion 
Membrane Transplantation 
Moreno Menghini
a    Stephanie L. Watson
b    Martina M. Bosch
a  
aDepartment of Ophthalmology, University Hospital of Zurich, Zurich, Switzerland; 
bSave Sight Institute, The University of Sydney, Sydney, N.S.W., Australia 
 
 
Key Words 
Mitomycin C · Pterygium · Corneal melting · Amniotic membrane · Lamellar 
keratoplasty 
 
 
Abstract 
Purpose: To report the management of a case of corneal melting two weeks after pterygium 
excision with intraoperative topical mitomycin C (MMC).  
Methods: Case report.  
Results: A 57-year-old male was referred to our Department for therapy of rapidly 
progressive corneal melting two weeks after primary pterygium surgery with MMC (0.2 
mg/ml) in September 2009. Initial treatment consisted of topical and systemic 
immunosuppression along with topical antibiotics. Eight days after presentation, the patient 
underwent successful lamellar keratoplasty and amnion membrane transplantation. 
Subconjunctival injection of triamcinolone (40 mg/ml) and topical bevacizumab were used to 
manage the increased fibrovascular activity around the site of the former pterygium.  
Conclusion: Topical use of MMC during pterygium surgery may be related to serious 
postoperative complications such as progressive inflammatory corneal melting. The etiology 
may be multifactorial, which is related to MMC-induced inflammation and/or induced 
apoptosis. A therapeutic option is the described combination of systemic and local anti-
inflammatory treatment along with lamellar keratoplasty and amniotic membrane 
transplantation. Adjunctive therapy may be needed if recurrence occurs. 
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Introduction 
Current research demonstrates that pterygium is a proliferative disease with 
hyperplastic growth of the corneoconjunctival fibrovascular tissue onto the cornea [1]. 
Surgical therapy can be used to successfully manage pterygia; however, recurrence 
remains a problem [2]. 
To reduce recurrence, surgical management may include autoconjunctival grafting 
[3], lamellar keratoplasty [4], amniotic membrane transplantation [5], and mitomycin C 
(MMC) [6]. Autologous conjunctival grafting has been shown to be the best technique, 
as it has low recurrence and adverse events rates [7]. Technically easier and therefore 
widely applied with primary pterygium excision is MMC. MMC is an antibiotic isolated 
from Streptomyces caespitosis, which interferes with RNA, DNA and protein synthesis. 
The topical use to prevent pterygium recurrence was first described in 1963 in Japan 
[8]. Though significantly reducing recurrence rates, MMC can cause scleral necrosis, 
secondary glaucoma, iritis, cataract, corneal edema, corneal perforation, and 
endophthalmitis [9]. The overall incidence of scleral necrosis after pterygium surgery 
has been reported as 0.2–4.5% with higher rates being linked to the use of MMC [10]. 
Scleral thinning can occur as early as one week postoperatively or even years after the 
use of topical MMC and is independent of intra- or postoperative delivery [11]. The 
management of surgically induced scleral necrosis associated with MMC post-
pterygium is complex and shows variable success. 
The purpose of this report is to present a case of a serious complication after 
intraoperative MMC administration in order to illustrate a successful management 
strategy:  the use of surgical repair by lamellar keratoplasty and amniotic membrane 
along with the control of ocular surface inflammation. 
Case Report 
A 57-year-old male was referred to the Department of Ophthalmology at the University Hospital of 
Zurich, Zurich, Switzerland, for the treatment of progressive painful peripheral corneal melting in the 
left eye two weeks after pterygium surgery with intraoperative MMC. Primary excision had been 
performed at another institution, using a bare sclera technique combined with application of 0.2 
mg/ml MMC to the scleral bed for 2 min. Primary closure of the conjunctiva had been achieved by a 
continuous suture with Vicryl® 8-0 (Ethicon Inc., Blue Ash, Ohio, USA). The postoperative 
management consisted of Tobradex® eye drops tid (3 mg tobramycin and 1 mg dexamethasone/1 ml; 
Alcon Laboratories Inc., Fort Worth, Tex., USA). After one week, the patient was changed to Floxal 
SDU® eye drops (Ofloxacin; Bausch and Lomb, Rochester, N.Y., USA) and 5 g vitamin A® ointment tid 
(vitamin A; Bausch and Lomb). 
At first presentation, his best corrected visual acuity (OD +1.75 sph/Øcyl; OS +1.25/Øcyl) was 
20/20 in the right eye and 20/60 in the left eye. The patient reported he had strictly adhered to the 
prescribed postoperative regimen and denied any other medical conditions, including any rheumatic 
disease. On slit-lamp examination, the left eye showed a nasal crescent-shaped area of corneal 
ulceration measuring 2.5 × 2.0 mm reaching Descemet’s membrane with adjacent severe conjunctival 
and scleral injection (fig. 1). Anterior chamber assessment showed concomitant mild cellular and 
fibrin reaction. His corneal smears, looking for evidence of a bacterial, viral and/or fungal infection, 
were negative. Complete blood count, electrolytes and inflammatory markers were also within 
normal ranges. In particular, immunological testing did not reveal any pathological elevation of ANA 
or ANCA.  
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The patient was admitted for pulse corticosteroid therapy with 0.1% Dexafree® UD eye drops 
every 2 h (dexamethasone; Théa Pharma, Clermont-Ferrand, France) and 250 mg Solu-Medrol® tid 
intravenously (methylprednisolone; Pfizer AG, New York, N.Y., USA). Floxal SDU eye drops were given 
every 2 h as a prophylaxis against infection. To inhibit collagenolysis, the patient was treated with 
100 mg Vibramycin® bid orally (doxycycline; Pfizer, New York, N.Y., USA) and 10% acetylcysteine eye 
drops qid. In addition, 500 mg Valtrex® tid orally (Valacyclovir; GlaxoSmithKline, London, UK) was 
prescribed until the diagnostic viral results were reported negative. Corneal melting stabilized under 
this treatment and ocular surface inflammation was reduced. Eight days after admission, when 
inflammation was under control, debridement of the corneal ulcer, recession of the adjacent 
conjunctiva, lamellar keratoplasty and amnion membrane transplantation covering the entire 
epithelial defect were successfully performed. 
The first postoperative day showed a well-positioned lamellar corneal transplant. Local 
corticosteroid and antibiotic treatment was tapered and systemic corticosteroid therapy was ceased 
ten days postoperatively. By the third postoperative week, increased superonasal fibrovascular 
activity was observed at the limbus. This was interpreted as impending recurrence of the pterygium 
and the patient received 0.5 ml Kenacort® 40 mg/ml subconjunctivally (triamcinolone; Dermapharm 
AG, Grünwald, Germany). Local antibiotic treatment with Floxal SDU was ceased four weeks 
postoperatively. 0.1% Dexafree UD eye drops were continued tid until ten weeks postoperatively and 
then replaced by FML Liquifilm® eye drops bid (fluorometholone; Allergan AG, Irvine, Calif., USA). 
On follow-up, four and a half months after surgery, spectacle-corrected visual acuity was 20/20. 
The Javal-Schiötz Ophthalmometer® (Haag-Streit AG, Bern, Switzerland) showed an irregular 
astigmatism of –1.5 dpt at 100°, which was confirmed with the Oculus-Pentacam® (Oculus GmbH, 
Wetzlar, Germany). Slit-lamp examination revealed a lamellar transplant, a few stromal parapupillary 
opacities nasally and a deep and quiet anterior chamber. The conjunctiva bordering the nasal cornea 
was slightly inflamed with an area of intensive vascularization and thickening (fig. 2). To minimize 
ocular surface inflammation, all sutures were removed and a subconjunctival injection of 0.6 ml 
Kenacort was given. Additionally, FML Liquifilm drops were replaced with 0.1% Dexafree UD qid. 
After a few weeks of slight regression, regrowth of the fibrovascular pannus was observed at the 
edge of the lamellar graft and 5 mg/ml bevacizumab eye drops (hospital pharmacy, University 
Hospital of Zurich, Zurich, Switzerland) were then given topically for 4 weeks. Six months 
postoperatively another subconjunctival Kenacort depot was placed. Superficial inflammation was 
then stabilized. A new formation of anterior synechiae extending through the three o’clock position at 
the former site of corneal melting was detected. At 14 months postoperatively a slight increase in 
vascularization was noted at the edge of the amnion patch. A fourth subconjunctival injection of 
Kenacort was given and the patient was continued on FML Liquifilm drops once daily for another 4 
months. No recurrence was noted at 24 months. 
Discussion 
This case illustrates a severe complication after bare sclera excision of a pterygium 
with intraoperative application of MMC to the scleral bed. Successful management was 
achieved through control of the inflammatory process and the combination of a 
lamellar keratoplasty and amnion membrane patch to prevent the impending corneal 
perforation. The amnion membrane transplant (with its anti-inflammatory properties) 
together with locally and systemically applied corticosteroid drugs were used to 
control the inflammation. Adjunctive therapy with subconjunctival steroids and anti-
vascular endothelial growth factor (VEGF) drugs was needed to treat a minor 
recurrence in the postoperative period. 
The aims of the primary surgery were not only to fully excise the pterygium, but also 
to prevent its recurrence. Mitomycin is utilized as ancillary treatment due to its 
antiproliferative effects. These irreversible effects of MMC might be the only cause of 
our patient’s postoperative complication. On the other hand, apoptosis and necrosis  
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might also have been triggered by the inflammatory properties of the pterygium and its 
excision. 
This severe complication threatened the tectonic integrity of the globe. Our primary 
goal, therefore, had been to surgically restore the integrity of the cornea, which was 
successfully achieved with lamellar keratoplasty. MMC-induced complications are 
associated with ocular surface inflammation, which can lead to a further deterioration 
of the clinical situation. Our goal, therefore, was not only to restore the full corneal 
thickness, but also to control the ocular surface inflammation with corticosteroids and 
tetracyclines. An additional anti-inflammatory effect was achieved by the amnion 
membrane transplantation. Furthermore, the timely recognition and treatment of an 
impending recurrence, with subconjunctival triamcinolone injection and anti-VEGF 
drugs, were crucial in stopping the recurrence. Several studies have recently 
emphasized the importance of VEGF in the development and recurrence of pterygium 
[12]. 
Despite the above-mentioned treatment, the formation of anterior synechiae 
extending through the three o’clock position at the former site of corneal melting could 
not be prevented. It remains unclear whether the synechiae were triggered by corneal 
microperforations most probably existing at referral or as a consequence of surgical 
intervention. Since the growth of the synechiae was progressive, a possible etiology is 
chronic inflammation, which may have been due to the irreversible damage to the 
tissue on the cell level caused by MMC. 
Recently described surgical options to reduce the recurrence of pterygium are 
recommended alternatives to bare sclera surgery [9]. The conjunctival autograft 
described by Kenyon et al. [3] shows low recurrence rates with minimal complications 
and is nowadays the preferred choice of many surgeons. In addition to the conjunctival 
autograft, limbal stem cell transplantation has been introduced to reconstruct the 
excised pterygial area as anatomically and physiologically correct as possible to 
theoretically reduce the recurrence rate [13]. However, some studies have shown that 
the recurrence rates after limbal stem cell transplantations are comparable with 
conjunctival autograft surgery alone [14]. Another surgical option in the primary 
treatment of pterygium is amniotic membrane transplantation. Despite the 
antiscarring, anti-angiogenic, and anti-inflammatory properties of amnion membrane, 
recent studies have found no advantage in terms of recurrence rates compared to 
conventional treatments, and some authors have even reported unacceptably high 
recurrence rates [5]. Recently, fibrin glue has been used to avoid suture-related 
complications [15]. The major drawbacks regarding fibrin glue are its costs, bovine 
contents, and the potential risk of transmitting infections [9]. 
Our case demonstrates a successful management of a severe MMC-induced 
complication. The corneal integrity was effectively repaired with lamellar keratoplasty 
and the inflammation was controlled by amniotic membrane grafting as well as the 
application of corticosteroids and tetracyclines. Considering the potential adverse 
events with the use of MMC, we believe that despite the technical challenge and the 
longer surgical time, the conjunctival autograft technique should be used to treat 
primary pterygia.  
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Fig. 1. The left eye at initial presentation showing a nasal crescent-shaped area of corneal ulceration 
(2.5 × 2.0 mm), extending to Descemet’s membrane. There is considerable adjacent severe 
conjunctival and scleral injection. 
 
 
 
Fig. 2. At 5 months after the lamellar keratoplasty and amniotic membrane patch graft, an area of 
intense vascularization and thickening of the conjunctiva was noted at the edge of the graft. 
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